[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-abscess\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-abscess":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,74,94,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100555982","liver-gut-axis-study-through-identification-of-liver-disease-specific-microbiome-100555982",false,"NCT06519162","Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome","Exploration of Liver-gut Axis Through Identification of Liver Disease-specific Microbiome","LGAS","Inclusion Criteria:\n\n* Adults aged 19 years and older diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, who have consented to participate in this study at Chungnam National University Hospital.\n* Adults aged 19 years and older, who are cohabitants of patients diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, and have consented to participate in this study at Chungnam National University Hospital.\n\nB. Exclusion\n\nExclusion Criteria:\n\n* Individuals under the age of 19.\n* Patients or guardians who do not consent to participate in the study",true,"ALL","19 Years",{"count":21,"type":22},3000,"ESTIMATED","OBSERVATIONAL","In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.",[26,27,28,29,30],"Autoimmune Hepatitis","Primary Sclerosing Cholangitis","Non-Alcoholic Fatty Liver Disease","Liver Abscess","Primary Biliary Cirrhosis",[32,33,34],"Liver Diseases","Microbiota","Immune System","RECRUITING","2026-03-19",{"date":38,"type":39},"2026-03-20","ACTUAL",{"date":41,"type":39},"2024-07-08",{"date":43,"type":22},"2029-07-08",{"name":45,"class":46},"Chungnam National University Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100581193","phase-3-empirical-intravenous-beta-lactam-plus-metronidazole-vs-oral-cefixime-plus-metronidazole-for-the-treatment-of-liver-abscess-100581193","NCT06847126","Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess","Comparison of Empirical Intravenous Beta-Lactam Antimicrobials Plus Metronidazole and Oral Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess: an Open Label Randomized Controlled Clinical Trial","Inclusion Criteria: All symptomatic patients with liver abscess verified by radiological imaging, either by computed tomography (CT) scan or ultrasound (USG), regardless of gender (male or female) and age ≥ 18 years, will be screened for registration in the study.\n\n\\-\n\nExclusion Criteria: Patients with past history of liver abscess, chronic kidney disease (CKD), hypersensitivity to either Metronidazole or Cefixime or Beta-lactam antimicrobials will not be allowed to participate in the study. Patients with organ dysfunction with shock (blood pressure \\\u003C 90\u002F60 mmHg), acute respiratory distress syndrome requiring oxygen therapy (PaO2\u002FFiO2 ≤ 300 or SpO2 ≤92%), encephalopathy (altered sensorium with GCS \\\u003C 15), acute kidney injury (increase in serum creatinine to ≥ 1.5 times from the baseline or serum creatinine ≥ 1.5) and not able to take orally will not be considered for participation in the study. Patients who are pregnant, have already received antimicrobials for more than 48 hours before to admission, or are receiving blood thinners such as antiplatelets or anticoagulants within 4 weeks of presentation and are unwilling to provide informed consent will also be excluded from the trial.\n\n\\-","18 Years",{"count":57,"type":22},220,"INTERVENTIONAL",[60],"PHASE3","Liver abscess (LA) is potentially life threatening medical emergency requiring prompt medical intervention. The backbone of therapy is prompt empirical antimicrobial with or without percutaneous drainage\u002F aspiration of the abscess. The standard care for liver abscess includes empirical antimicrobials consisting both antibacterial and amoebicidal agents along with percutaneous drainage or aspiration of the collection. The antimicrobial regimen should cover against E. histolytica until microbial etiology is established or liver abscess of amoebic etiology is ruled out. But still there is no straightforward general agreement or evidence based on clinical studies regarding the standard protocol for empirical antimicrobials concerning choice, route of administration or duration of antimicrobials therapy. Most of the experts preferred intravenous antimicrobials over oral antimicrobials for the treatment of liver abscess with or without complication. But, there is no clinical trial evidence to support the rational of using intravenous antibiotics up front instead of oral antimicrobials. Recently published institutional study also suggested that empirical oral antimicrobials (Cefexime\u002FCiprofloxacin) were efficacious for the treatment of uncomplicated liver abscess, successfully managing around 90 % cases of liver abscess. When treating a liver abscess, the choice of antimicrobials and the administration technique must be specially tailored depending upon the existence of complications and the patient's clinical reaction. In the absence of clinical trials, the rational for using of intravenous broad spectrum antibiotics upfront instead of oral antimicrobials for the treatment of liver abscess with or without complications is doubtful and may appear injudicious contributing future rise of antimicrobial resistance. The use of intravenous antibiotics upfront may also unnecessarily lengthen hospital stays, enhance therapeutic expenditure, and raise the risk of hospital-acquired infections in patients who are capable for taking antimicrobials orally. Oral antimicrobials strategy will promote earlier discharge from the hospital and the patient can return to usual activities earlier. This study aims to provide valuable insights into the comparison and efficacy of empirical intravenous Beta-lactam antimicrobials plus Metronidazole and oral Cefixime plus Metronidazole therapy for the treatment of uncomplicated liver abscess. In this randomised controlled open label clinical trial all the patients with newly diagnosed liver abscess confirmed with radiology imaging, either by USG or CT scan, presenting at emergency or medical OPD will be screened for enrolment in the study. Following written informed consent from the participants and\u002For their legal guardian, those who meet the inclusion and exclusion criteria will be recruited in the study. Subsequently the participants will be randomized into either intravenous or oral antimicrobial group. The intravenous-group will receive Beta-lactam antimicrobials (i.e Piperacillin-Tazobactum 4.5g q 8 hourly or Ceftriaxone 1g q 12 hourly or Meropenem 1g q 8 hourly or Imipenem-Cilastatin 500mg q 6 hourly) Plus intravenous Metronidazole 750mg q 8 hourly for 2weeks. The oral-group will receive tablet Cefixime 200 mg q 12 hourly plus tablet Metronidazole 800 mg q 8 hourly for 2 weeks. Both the group will be provided standard care of therapy including percutaneous drainage or aspiration as per indication and will be followed up for 8 weeks. The primary outcome of clinical cure and secondary outcome of incidence of treatment failure, mortality, duration of antimicrobial therapy, recurrence, adverse drug reaction (ADR), complications will be compared between the groups.",[29],[64],"Liver Abscess, Empirical antimicrobials, Beta-lactam antimicrobials, Intravenous, Oral, Cefixime, Metronidazole","2025-04-10",{"date":67,"type":39},"2025-04-13",{"date":69,"type":39},"2025-02-25",{"date":71,"type":22},"2026-06-30",{"name":73,"class":46},"Post Graduate Institute of Medical Education and Research, Chandigarh",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100581586","characteristics-and-treatment-outcome-of-liver-abscesses-an-observational-study-100581586","NCT06852235","Characteristics and Treatment Outcome of Liver Abscesses: An Observational Study","Inclusion Criteria:\n\n* Diagnosis of LA will be based on typical appearance on ultrasound (US) or computed tomography (CT) of abdomen with clinical features consistent with the diagnosis (fever, chills, jaundice, right upper quadrant pain\u002Fepigastric discomfort).\n* US or CT-guided aspiration of pus from a hepatic lesion.\n* Complete resolution of radiological abnormalities following antimicrobial therapy.\n\nExclusion Criteria:\n\n* Liver abscess that occurs secondary to hydatid cyst.\n* Liver abscess associated with underlying malignancy.\n* Patient with incomplete medical records.",{"count":81,"type":22},70,"1. To assess the frequency, clinical presentation, microbiological and radiological characteristics of liver abscesses.\n2. To evaluate the management plan and treatment outcome of liver abscess.\n3. To study risk factors of liver abscess.",[29],"NOT_YET_RECRUITING","2025-02-26",{"date":87,"type":39},"2025-02-28",{"date":89,"type":22},"2025-03-15",{"date":91,"type":22},"2027-06-01",{"name":93,"class":46},"Assiut University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":47},"100554994","a-joint-model-based-on-deep-learning-to-predict-multidrug-resistant-klebsiella-pneumoniae-liver-abscess-100554994","NCT06506318","A Joint Model Based on Deep Learning to Predict Multidrug-resistant Klebsiella Pneumoniae Liver Abscess","Combining Image-clinical Model Based on Deep Learning and Radiomics to Predict Multidrug-resistant Klebsiella Pneumoniae Liver Abscess","CLASS2401","Inclusion Criteria:\n\n* Patients diagnosed as pyogenic liver abscess and was proved by surgery or interventional process.\n* Patients had accepted abdominal enhance CT scans before surgery or interventional process.\n\nExclusion Criteria:\n\n* Patients diagnosed with other types of liver abscess such as amoeba.",{"count":103,"type":22},550,"The goal of this observational study is to train a deep learning-based model to predict multidrug-resistant Klebsiella pneumoniae liver abscess and evaluate it on a multi-center database.",[29],[107],"Deep-learning; Liver Abscess","2024-07-11",{"date":110,"type":39},"2024-07-17",{"date":112,"type":39},"2024-01-01",{"date":114,"type":22},"2025-03-01",{"name":116,"class":46},"Shengjing Hospital",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100553246","prediction-and-prognostic-analysis-of-liver-abscess-formation-after-transcatheter-arterial-chemoembolization-for-hepatocellular-carcinoma-chance-2407-100553246","NCT06483594","Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)","Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma : a Retrospective Multicenter Nested Case-control Study (CHANCE 2407)","Inclusion Criteria:\n\n1. Case group inclusion criteria:\n\n   1. Time period of inclusion: 2009-2023 (15 years)\n   2. Patients with HCC diagnosed by clinical or pathological criteria according to the National Health Commission guidelines for the diagnosis and treatment of primary liver cancer who underwent TACE after surgery and developed postoperative liver abscess.\n   3. Appendix: Diagnostic criteria for liver abscess after TACE:\n\n   Condition 1: CT images show typically low-density lesions with or without air and fluid levels\n\n   Condition 2:\n   * positive blood culture\n   * Percutaneous drainage or aspiration is purulent or culture-positive\n   * Symptoms of infection such as fever\u002Fchills, accompanied by elevated inflammatory markers such as white blood cell count, C-reactive protein, or procalcitonin.\n2. Control group inclusion criteria\n\n   1. Patients with HCC without liver abscess who underwent TACE in the same center within the week of treatment in the case group.\n\n      \\-\n\n      Exclusion Criteria:\n\n   \u003C!-- -->\n\n   1. Clinical and follow-up data were incomplete\n   2. Loss to follow-up",{"count":125,"type":22},400,"Liver abscess is a rare but serious complication of hepatocellular carcinoma after TACE, with an incidence of less than 1% reported in previous literature. Studies have shown that history of biliary tract disease, tumor size, embolization materials and embolization endpoint selection may be related to the occurrence of abscess. In recent years, with the wide application of targeted and immune drugs, there have been reports of multiple cases of liver abscess after single target immunotherapy for liver cancer, and there have also been studies showing that TACE combined with targeted immunotherapy can significantly increase the degree of liquefaction necrosis and increase the risk of liver abscess. However, these studies are single-center reports with small sample size and low level of evidence. Therefore, it is of great clinical significance to explore the risk factors of liver abscess after TACE and build a prediction model by using multi-center and large sample data. The formation of liver abscess after TACE means a large range of tissue liquefaction necrosis. There are reports of high incidence of early recurrence and metastasis of liquefaction necrosis. Some studies also show that tumor necrosis is more complete when liver abscess is combined with complete remission. In previous studies, ORR in patients with liver cancer complicated with liver abscess ranged from 18.75%-100%, with significant differences in reports from different centers. The effect of specific abscess formation on TACE efficacy of liver cancer remains to be determined. Therefore, the second research focus of this project is to explore the effect of liver abscess formation after TACE on prognosis of liver cancer.",[128,129,29],"TACE","HCC - Hepatocellular Carcinoma","2024-06-28",{"date":132,"type":39},"2024-07-03",{"date":134,"type":22},"2024-06-30",{"date":136,"type":22},"2025-06-30",{"name":116,"class":46}]